Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta

Phase 4 Completed 79 enrolled Oregon Health and Science University Eli Lilly and Company · collab National Center for Research Resources (NCRR) · collab National Institutes of Health (NIH) · collab Osteogenesis Imperfecta Foundation · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the effectiveness of teriparatide (FORTEO), which is human parathyroid hormone 1-34, for increasing bone mass and improving bone structure in adults affected with Osteogenesis Imperfecta (OI).

Timeline

Start: 2005-06
Primary completion: 2011-01
Completion: 2011-01

Publications

Orwoll ES, Shapiro J, Veith S, Wang Y, Lapidus J, Vanek C, Reeder JL, Keaveny TM, Lee DC, Mullins MA, Nagamani SC, Lee B. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest. 2014 Feb;124(2):491-8. doi: 10.1172/JCI71101. Epub 2014 Jan 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Teriparatide	Protein / enzyme biologic	20 ug	Subcutaneous

Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta

Summary

Timeline

Publications

Drugs

Indications